Search Results
Your search for ,OUr matches 10724 pages
Showing 2051 - 2100Nationwide Study Finds Higher Rates of Cancer Mortality, Increasing Cases of Early-Onset Colorectal Cancer Among American Indian and Alaska Native Individuals
New findings revealed that overall cancer mortality among American Indian and Alaska Native patients was 18% higher than among White patients despite similar cancer incidence, according to a new study published by Kratzer et al in CA: A Cancer Journal for Clinicians. The findings included the first ...
Prevalence of Mismatch Repair Deficiency in Rectal Adenocarcinoma in a Prospective Screening Program
As reported in a letter published in The New England Journal of Medicine by Papke et al, data from a prospective biopsy screening program at a large gastrointestinal pathology group indicate that approximately 3% of rectal adenocarcinomas are mismatch repair (MMR)-deficient. Study Background As...
My White Coat Doesn’t Fit
There I was, crying once again all the way from the hospital’s parking lot to my apartment, into the shower, and while trying to fall asleep. This had become the norm during my internal medicine residency. For years, I tried hard every day to be someone else to fit in. It started with off-hand...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main takeaway is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to...
Expert Point of View: Glenn J. Hanna, MD, and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Yuan Yuan, MD, PhD, Joins Cedars-Sinai Cancer Medical Center as Director of Breast Oncology
Cedars-Sinai Cancer Medical Center recently announced the appointment of Yuan Yuan, MD, PhD, a breast medical oncologist and physician scientist who specializes in triple-negative breast cancer and breast cancer immunotherapy, as Director of Breast Oncology. Finding Cutting-Edge Therapies...
Phase III FRESCO-2 Trial of Fruquintinib Meets Primary Endpoint in Metastatic Colorectal Cancer
HUTCHMED (China) Limited recently announced that the global phase III FRESCO-2 trial evaluating the investigational use of the anti–vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor fruquintinib met its primary endpoint of overall survival in patients with advanced, refractory...
ASCO Treatment Guidance for Metastatic Castration-Resistant Prostate Cancer Updated to Include LuPSMA
An updated ASCO guideline recommends lutetium-177–labeled PSMA-617 (LuPSMA), a targeted radioligand therapy, for patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with one prior line of androgen receptor pathway...
Prolonging Remission in Anti–PD-1 Refractory Melanoma With Tumor-Infiltrating Lymphocyte Therapy
For the first time in a multicenter randomized trial, T-cell therapy has been shown to improve outcomes in a solid tumor. In the phase III M14TIL trial, first-line or second-line treatment with tumor-infiltrating lymphocytes (TIL) led to a 50% reduction in disease progression or death from advanced ...
Erica Huelsmann, MD, Wins a Conquer Cancer Annual Meeting Merit Award
Erica Huelsmann, MD, a gynecologic oncology fellow at Fox Chase Cancer Center, Philadelphia, has been awarded a 2022 Conquer Cancer Merit Award by Conquer Cancer, the ASCO Foundation. The award, given at the 2022 ASCO Annual Meeting, supports researchers with projects that span many areas of...
Multilayered Approach to Financial Toxicity Solutions for Patients With Cancer and Their Families
With out-of-pocket costs of cancer care exceeding $21 billion in 2019, financial toxicity among patients and their families in the United States has become too prevalent to ignore. In fact, more than 50% of working-age survivors now report at least one material, psychological, or behavioral domain...
HPV Vaccine ‘Works Astonishingly Well’
The human papillomavirus (HPV) vaccine “works astonishingly well. It really prevents the kind of infections that cause cancer,” commented Ruanne Barnabas, MBChB, MSc, DPhil, MD, PhD, in an interview with The ASCO Post. “Other viral infections are difficult to protect against, or there might be...
Global Effort to Eliminate Cervical Cancer: HPV Vaccinations Are Steadily Increasing in the United States, but Barriers Still Exist
To achieve its goal of eliminating cervical cancer, the World Health Organization (WHO) is calling on all countries “to reach and maintain an incidence rate of below 4 per 100,000 women.” Doing so would depend on the following: A total of 90% of girls being fully vaccinated against human...
The Evolving Role of PI3K Inhibitors in Double-Refractory CLL
The treatment paradigm for chronic lymphocytic leukemia (CLL) continues to evolve in the first-line setting and beyond, with the availability of Bruton’s tyrosine kinase (BTK) inhibitors, the BCL2 inhibitor venetoclax, and novel combinations of these agents with anti-CD20 monoclonal antibodies....
With Newer Therapies, AML Diagnosis and Prognosis Evolve
For many years, treatment options for acute myeloid leukemia (AML) were limited mainly to the 7 + 3 regimen. However, more recently, a mini-explosion of AML therapies aimed at newly identified genetic targets makes discussions about treatment of this disease much more complicated. In fact, these...
New Directions for Cancer Care: Major Trends in U.S. Health Policy
The pace of cancer drug development may have accelerated over the past decade, but so too has the cost of care, which threatens to limit access for a large percentage of Americans in the decade to come. During the keynote lecture at the 2022 ASCO Quality Care Symposium, Ezekiel J. Emanuel, MD, PhD, ...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
Study Finds Nearly Half of Black Women With Metastatic Breast Cancer Never Receive Information About Clinical Trial Participation
When Stephanie L. Walker, RN, was diagnosed with metastatic breast cancer in 2015, she was not given information about an appropriate clinical trial or help navigating her way through the financial difficulties she was having after a stroke from complications of the cancer forced her to leave her...
How to Advance Antiracist Approaches to Patient Engagement in AYA Oncology and Research
Among the topics discussed at the 4th Global Adolescent and Young Adult Cancer Congress held online in December 2021 was the urgent need for clinicians, researchers, and advocates in adolescent and young adult (AYA) oncology to join forces to eradicate racist approaches to patient engagement in...
‘TRANSFORMING’ Our Thinking About Second-Line Therapy for High-Risk Large B-Cell Lymphoma: Bring in the CARs
As reported in The Lancet by Kamdar et al,1 and summarized in this issue of The ASCO Post, the international phase III TRANSFORM trial was completed in 184 patients with primary refractory or early (≤ 12 months) relapsed large B-cell lymphoma (LBCL). Patients were randomly assigned to receive...
Shorter Course of Hypofractionated Radiation Therapy Yields Comparable Results to Conventional Radiotherapy for Patients With Nonmetastatic Soft-Tissue Sarcoma
Patients with nonmetastatic soft-tissue sarcoma who need preoperative radiation therapy can safely receive hypofractionated treatment for 3 weeks instead of 5 weeks, with comparable tumor control and no increased risk of major complications in wound healing, according to a new study published by...
Phase I Trial Shows Experimental Mini-Protein May Be Able to Inhibit the Cancer-Driving MYC Gene
Researchers have found that a new drug may be able to target—and for the first time, inhibit—the function of the MYC gene. Until now, no other drug has been able to do this safely and effectively, according to findings from a phase I clinical trial published by Garralda et al in the European...
Indian Trial Explores Addition of Low-Dose Nivolumab to Chemotherapy in Advanced Head and Neck Cancer
In an Indian single-center phase III trial reported in the Journal of Clinical Oncology, Vijay Patil, MBBS, MD, DM, and colleagues found that the addition of low-dose nivolumab to triple metronomic chemotherapy significantly improved overall survival in patients with newly diagnosed or recurrent...
PET-Adapted Therapy for Bulky Stage I/II Classical Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Ann S. LaCasce, MD, MMSc, and colleagues, the phase II CALGB 50801/Alliance trial has shown that a positron-emission tomography (PET)-adapted treatment strategy allowed many patients with bulky stage I/II classical Hodgkin lymphoma to avoid...
Cell-Free DNA Profiling in Patients With Advanced Cancers May Lead to Early Detection of Myeloid Malignancies
Researchers have found that an incidental finding of clonal hematopoiesis in liquid biopsies can be used to trigger hematologic tests to assess the risk of developing myeloid malignancies, according to a new study published by Tagliamento et al in the European Journal of Cancer. The findings were...
Sequential Dosing of Olaparib and Adavosertib in Patients With Advanced Tumors
Olaparib and adavosertib can be safely used to treat patients with cancers that are driven by certain mutations occurring in response to DNA damage if they are given in sequence rather than concurrently, according to a novel study published by Yap et al in the European Journal of Cancer. The...
Expert Point of View: Glenn J. Hanna, MD and Sherene Loi, MD, PhD
The ASCO Post asked for comment from Glenn J. Hanna, MD, Director of the Center for Salivary and Rare Head and Neck Cancers, Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School. Dr. Hanna said it is important to put the findings of KEYNOTE-4121 into context...
Expert Point of View: Robin Kate Kelley, MD
Robin Kate Kelley, MD, Professor of Clinical Medicine at the University of California, San Francisco, was invited to discuss the results of LEAP-002.1 She said the main take-away is that lenvatinib monotherapy is active as a preferred first-line agent for fit patients who have contraindications to ...
Expert Point of View: Natasha Leighl, MD
“Platinum-ineligible patients are typically excluded from clinical trials, yet they represent the majority of patients that we diagnose and treat—patients with poor performance status and comorbidities,” said invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto....
IPSOS Trial: Platinum-Ineligible Patients With NSCLC May Gain Survival Benefit From Atezolizumab Therapy
In platinum-ineligible patients with advanced non–small cell lung cancer (NSCLC), first-line treatment with the PD-L1 checkpoint inhibitor atezolizumab improved overall survival by an absolute value of about 1 month but almost doubled the rate of 2-year overall survival compared with chemotherapy...
Expert Point of View: Natasha Leighl, MD
“CodeBreaK 200 clearly establishes sotorasib as the new standard of care, replacing docetaxel as second- or third-line therapy for advanced KRAS G12C–mutated lung cancer,” stated invited discussant Natasha Leighl, MD, of the Princess Margaret Cancer Centre, Toronto. “Sotorasib improved...
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 106,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people over the age of 50 years, which is ...
Researchers Discover Differences in Response to Pembrolizumab Among Patients With Endometrial Cancer
Researchers discovered a differential clinical response to pembrolizumab in patients with Lynch-like (mutated) vs methylated microsatellite instability–high endometrial cancer, outlining characteristics of patients who may derive benefit from immune checkpoint blockade antibodies, according to new...
Increased Mortality From Comorbid Cancer and Cardiovascular Disease Associated With Increased Social Vulnerability
In a U.S.-based cross-sectional study reported in JACC: CardioOncology, Sarju Ganatra, MD, of Lahey Hospital & Medical Center, Burlington, Massachusetts, and colleagues found that mortality from comorbid cancer and cardiovascular disease (CVD) was significantly higher in counties with higher...
Neoadjuvant Immunotherapy With Relatlimab and Nivolumab in Stage III Melanoma
The combination of immune checkpoint inhibitors relatlimab and nivolumab for patients with stage III melanoma given before surgery was safe and completely cleared all viable tumor in 57% of patients in a phase II study, according to findings published by Amaria et al in Nature. In addition to...
Rogaratinib vs Chemotherapy in Previously Treated Patients With Advanced Urothelial Carcinoma and FGFR1/3 mRNA Overexpression
As reported in the Journal of Clinical Oncology by Cora N. Sternberg, MD, and colleagues, interim analysis of the phase II portion of the phase II/III FORT-1 trial has shown similar objective response rates with the oral FGFR1–4 inhibitor rogaratinib vs chemotherapy in previously treated patients...
Concurrent Bevacizumab and Reirradiation vs Bevacizumab Alone in Recurrent Glioblastoma
As reported in the Journal of Clinical Oncology by Christina I. Tsien, MD, and colleagues, the phase II NRG Oncology/RTOG1205 trial has shown improved progression-free—but not overall—survival with concurrent bevacizumab and reirradiation vs bevacizumab alone in patients with recurrent...
Can Genetic Mutations Impact Radiation Sensitivity?
A new study identified both common and rare genetic mutations that may impact radiation resistance and sensitivity, an important step toward providing more individualized and effective radiotherapy for patients with cancer, according to findings published by Gopal et al in Clinical Cancer ...
Minority Patients Face Longer Waits for Non–Small Cell Lung Cancer Treatment
A new study has revealed significant racial disparities in how quickly minority patients with non–small cell lung cancer receive radiation therapy compared with their White counterparts, according to findings published by Rekulapelli et al in Health Equity. Researchers reviewed data from more than...
New Cervical Screening Test Could Predict Cell Changes Years Before They Occur
Researchers have developed a new swab test that can identify origins of potentially dangerous cervical cell changes up to 4 years before they happen, according to a new study published by Barrett et al in Genome Medicine. Scientists found that the new cervical screening method was more sensitive...
Expert Point of View: Christian U. Blank, MD, PhD
Christian U. Blank, MD, PhD, Professor of Internal Medicine, staff member at Netherlands Cancer Institute, Professor at the University of Regensburg in Germany, and founding member of the International Neoadjuvant Melanoma Consortium, was the invited discussant of the MD Anderson study of...
Analysis of Radiotherapy and Breast Cancer Recurrence in the RxPONDER Trial
Do patients with breast cancer and a low 21-gene recurrence score need regional node irradiation to reduce their risk of locoregional recurrence? An analysis of RxPONDER trial data suggests only a randomized clinical trial devoted to this question can provide a decisive answer. An analysis of data...
2022 Annual Report to the Nation on the Status of Cancer Released
Overall cancer death rates continued to decline among men, women, children, adolescents, and young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer. From 2014 to 2018, overall cancer...
Small Study Examines Repeated Convection-Enhanced Delivery of Topotecan for Recurrent Glioblastoma
In a single-center, small phase Ib trial reported in The Lancet Oncology, Spinazzi et al found that repeated and prolonged convection-enhanced delivery of topotecan prior to surgery was feasible in patients with recurrent glioblastoma and resulted in significant reduction in proliferating tumor...
AACR and ASCO Release Joint Policy Statement on Electronic Nicotine Delivery Systems
The American Association for Cancer Research (AACR) and ASCO have released a joint policy statement outlining the latest research on the use of e-cigarettes and other electronic nicotine delivery systems (ENDS) and recommendations for regulating these products to protect public health. The...
Response-Adapted Ultra–Low Dose Radiation Achieves Complete Response in Majority of Patients With Orbital Indolent B-Cell Lymphomas
Using a novel response-adapted ultra–low dose radiation therapy strategy, researchers at The University of Texas MD Anderson Cancer Center observed a 90% complete response rate in patients with orbital indolent B-cell lymphomas. Results were presented by Pinnix et al at the 2022 American Society...
Sexual Side Effects of Cancer Treatment Often Unaddressed With Female Patients
A new study has found that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs. Among patients receiving brachytherapy for prostate or cervical cancer at a high-volume cancer...
Medical Physicist Consults May Help Reduce Patient Anxiety and Increase Satisfaction With Radiation Care
Meeting with a medical physicist who can explain how radiation therapy is planned and delivered may reduce patient anxiety and increase patient satisfaction throughout the treatment process, according to a new study published by Burmeister et al in the International Journal of Radiation Oncology •...
Leader in Genitourinary Oncology, Nicholas J. Vogelzang, MD, FACP, FASCO, Dies at 72
Nicholas J. Vogelzang, MD, FACP, FASCO, an expert in the treatment of patients with renal cell carcinoma, died on September 20, 2022. Dr. Vogelzang was 72 years old. Son of a Preacher Dr. Vogelzang was born on December 13, 1949, in Holland, Michigan, the oldest of seven children, in a close-knit...
A Urologic Surgeon Shares His Insights on Robotic Radical Prostatectomy
In 2000, the da Vinci Surgical System broke new ground by becoming the first robotic surgery system approved by the U.S. Food and Drug Administration for general laparoscopic surgery. In its early years, robot-assisted radical prostatectomy was characterized by some in the surgical community as an...
